Skip to Content
  • Previous Rank
    72
  • Revenue 3 Yr Annual Growth Rate
    27%
  • Revenue 3 Yr Growth Rank
    53
  • EPS 3 Yr Annual Growth Rate
    42%
  • EPS 3 Yr Growth Rank
    44
  • Total Return 3 Yr Annual Rate
    4%
  • Total Return 3 Yr Rank
    94

Multiple sclerosis drug Tecfidera continues to boost revenue for this biotech–a stalwart of this list, appearing for the seventh time.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Information

Location
Cambridge, Mass.
Industry
Pharmaceuticals
Sector
Health Care
Current Streak2
Years on List7
CEO
George Scangos
Websitehttp://www.biogen.com
Revenue and net income for the four quarters ended on or before April 30, 2016.!Total return for the period ended June 30, 2016.

Revenue, Net Income

Revenue Past Four Quarters ($M)$10,936
Net Income Past Four Quarters ($M)$3,695

Growth Rates and Ranks

Revenue 3 Yr Growth Rank53
EPS 3 Yr Annual Growth Rate42%
EPS 3 Yr Growth Rank44
Total Return 3 Yr Annual Rate4%
Total Return 3 Yr Rank
94